Document Detail

Thrombolytic agents and anticoagulants.
MedLine Citation:
PMID:  8110627     Owner:  NLM     Status:  MEDLINE    
The medical and scientific communities, appreciating the pivotal role of thrombosis in the evolution and expression of atherosclerotic coronary artery disease, have embarked upon intense efforts to develop safe, effective, and affordable thrombolytic agents and anticoagulants. With an understanding that more is not always better, these new compounds, mutants, and derivatives will be designed specifically to impair, neutralize, or enhance several key components of well-characterized thrombotic and fibrinolytic processes. If efforts continue at the current pace, one or more "designer" thrombolytics and anticoagulants will be ready for Phase II or Phase III clinical trials in the near future.
R C Becker
Related Documents :
15586627 - Clinical potential of oral direct thrombin inhibitors in the prevention and treatment o...
12726807 - Virtual coronary cineangiography.
7655497 - Portal hypertension associated with anticardiolipin antibodies in a case of systemic lu...
2220767 - Acute myocardial infarction, non-bacterial thrombotic endocarditis, and disseminated in...
8619737 - Successful repair of a right ventricular rupture at the atrioventricular groove.
21183767 - Drug-eluting stents following rotational atherectomy for heavily calcified coronary les...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  7     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-03-31     Completed Date:  1994-03-31     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  825-8     Citation Subset:  IM    
Thrombosis Research Center, University of Massachusetts Medical School, Worcester 01655.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Designer Drugs*
Fibrinolytic Agents*
Reg. No./Substance:
0/Anticoagulants; 0/Designer Drugs; 0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influences of lipid-modifying agents on hemostasis.
Next Document:  Assurance against drug-induced death in patients with heart failure.